After search, choose a molecule or a kind of categories listed in the left to narrow down your filter. If you have any problems, please contact us!
Text Size:AAA

CD80 / B7-1 Antibody, Mouse MAb

DatasheetSpecific PreferencesReviewsResearch TopicsProtocols
B7-1/CD80Antibody Product Information
Antigen:Recombinant Human CD80 / B7-1 Protein (Catalog#10698-H08H)
Clone ID:01
Ig Type:Mouse IgG1
Formulation:0.2 μm filtered solution in PBS with 5% trehalose
Preparation:This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CD80 / B7-1 (rh CD80 / B7-1; Catalog#10698-H08H; Met 1-Asn 242; NP_005182.1). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
B7-1/CD80Antibody Usage Guide
Specificity:Human CD80 / B7-1
No cross-reactivity in ELISA with
Human CD28
Human B7-2
Human B7-H1
Mouse B7-H2
Human PDL2
Human cell lysate (293 cell line)

ELISA: 0.5-1 μg/mL

This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect Human B7-1. The detection limit for Human B7-1 is approximately 0.00975 ng/well.

Storage:This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD80, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

  • Greenfield EA, et al. (1998) CD28/B7 costimulation: a review. Crit Rev Immunol. 18(5): 389-418.
  • Zang X, et al. (2007) The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res. 13(18 Pt 1): 5271-9.
  • Mir MA, et al. (2008) Signaling through CD80: an approach for treating lymphomas. Expert Opin Ther Targets. 12(8): 969-79.
  • Related Products
    Product nameProduct name
    Size / Price
    List Price: $135.00  (Save $0.00)
    Price:$135.00      [How to order]
    Availsability:In Stock
      Recently Viewed Items